Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.65 |
| ▸ | IKZF3 | Q9UKT9 | 11/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | BRD3 | Q15059 | 6/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30389674 | 1.00 | CRBN (0.65) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21848644 | 0.99 | CRBN (0.65) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL30388938 | 0.95 | CRBN (0.58) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21848660 | 0.95 | CRBN (0.58) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21848663 | 0.94 | CRBN (0.58) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL30388965 | 0.94 | CRBN (0.58) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21848649 | 0.90 | CRBN (0.54) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21848747 | 0.90 | CRBN (0.52) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL21848724 | 0.90 | CRBN (0.52) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL23739668 | 0.90 | CRBN (0.55) | CRBNIKZF3DDB1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-04 | — | — | US | disclosed |
| CN-114085212-B | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-05-02 | — | — | CN | disclosed |
| CN-114085212-A | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-02-25 | — | — | CN | disclosed |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
| CN-110963994-B | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-02-08 | — | — | CN | disclosed |
| EP-3862348-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-08-11 | — | — | EP | disclosed |
| EP-3862348-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-08-11 | — | — | EP | disclosed |
| CN-110963994-A | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2020-04-07 | — | — | CN | disclosed |
| WO-2020064002-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | CUL4B, CUL4A, UBQLN1 | CRBN 23/4885IKZF3 219/4885DDB1 319/4885 |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CUL4B, CUL4A, UBQLN1 | CRBN 23/4885IKZF3 219/4885DDB1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.